好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Global vs. Focal White Matter Injury Demonstrates Varying Cerebral Visual Impairment
Child Neurology and Developmental Neurology
P5 - Poster Session 5 (5:30 PM-6:30 PM)
8-002

To determine the impact of neurovascular injury in childhood on cerebral visual impairment (CVI) as evaluated by visual-spatial processing using bedside virtual reality testing.

CVI, characterized by functional vision deficits, is not assessed in standard ophthalmological exams and can delay diagnosis and interventions. Multisystemic Smooth Muscle Dysfunction Syndrome (MSMDS), caused by R179H mutation in the ACTA2 gene is associated with diffuse white matter injury and arterial ischemic strokes. Pediatric strokes are commonly caused by focal disruption of blood flow to the brain affecting grey and white matter.

Using a virtual-reality dynamic visual search task, requiring searching for on-screen targets with increasing complexity, we prospectively characterized metrics of higher-order visual processing in pediatric stroke subjects (n=19), and MSMDS patients (n=4) as compared to healthy controls (n=13). Metrics – reaction time, gaze error, shifted ellipse area, success rate, and pursuit saccade ratio – were analyzed using Kruskal-Wallis and ANOVA tests and significant if p<0.05. An off-screen count metric confirmed task compliance.

While all cohorts had similar success rates, both MSMDS and pediatric stroke subjects showed longer reaction times to identify the target and higher gaze error than controls. Additionally, MSMDS subjects exhibited a larger shifted ellipse area and lower pursuit saccade ratios than controls. Perinatal and pediatric stroke subjects showed no differences, leading us to combine their results as one cohort.

Deficits exhibited by MSMDS and pediatric stroke subjects, despite similar success rates to controls, highlight the compensatory energy used to complete tasks. While plasticity and focality of pediatric stroke injury protect against CVI, globality in MSMDS injury correlates with increasingly more severe CVI. This highlights the need for clinical tools that can assess these difficulties with quantitative methods to guide therapies and improve functional outcomes.

Authors/Disclosures
Emily Da Cruz
PRESENTER
No disclosure on file
Diana Tambala (MGH) No disclosure on file
Anna Lynch No disclosure on file
Claire Manley (Mass. Eye and Ear) No disclosure on file
Melissa Bambery, Other (Massachusetts General Hospital) Ms. Bambery has nothing to disclose.
Daniel C. Kelly Mr. Kelly has nothing to disclose.
Kenda Alhadid, MD (Massachussets General Hospital) Dr. Alhadid has nothing to disclose.
Lotfi Merabet (Massachusetts Eye and Ear, Harvard Medical School) No disclosure on file
Patricia Musolino, MD, PhD An immediate family member of Dr. Musolino has received personal compensation for serving as an employee of EMD Sorono. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Minoryx Pharmaceuticals. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for IONIS Pharmaceuticals . Dr. Musolino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inozyme Pharma. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. An immediate family member of Dr. Musolino has or had stock in 2seventy Bio. An immediate family member of Dr. Musolino has or had stock in Editas Medicine. An immediate family member of Dr. Musolino has or had stock in Generation Bio. An immediate family member of Dr. Musolino has or had stock in Beam Therapeutics. An immediate family member of Dr. Musolino has or had stock in Ebotec . An immediate family member of Dr. Musolino has or had stock in Novonordisk. An immediate family member of Dr. Musolino has or had stock in Morphosys. The institution of Dr. Musolino has received research support from National Institute of Health-NINDS-R01. The institution of Dr. Musolino has received research support from Angea Biotherapeutics. The institution of Dr. Musolino has received research support from Minoryx Pharmaceuticals. The institution of Dr. Musolino has received research support from Belanger Foundation. The institution of Dr. Musolino has received research support from Rozwat Family Foundation. The institution of Dr. Musolino has received research support from Dooley Family Foundation. Dr. Musolino has received intellectual property interests from a discovery or technology relating to health care. Dr. Musolino has received publishing royalties from a publication relating to health care.